A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 1149-1156

  Santana, Lourdes ^a   Uriarte, Eugenio ^a   González Díaz, Humberto ^a,c   Zagotto, Giuseppe ^a   Soto Otero, Ramón ^b   Méndez Álvarez, Estefanía ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF PADOVA   (Italy)

^c CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; COUMARIN DERIVATIVE; MONOAMINE OXIDASE A INHIBITOR; OCTANOL; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PARTITION COEFFICIENT; POLARIZATION; PROBABILITY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; TECHNIQUE; THEORETICAL STUDY; VALIDATION PROCESS;

ALGORITHMS; ANIMALS; BRAIN; COUMARINS; ISOENZYMES; MALE; MARKOV CHAINS; MITOCHONDRIA; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, SPRAGUE-DAWLEY;

EID: 32344446616     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0509849     Document Type: Article

References (46)

1. Dostert, P.; Strolin Benedetti, M.; Jafre, M. Monoamine Oxidase: Basic and Clinical Frontiers; Elsevier: Amsterdan, 1982.
2. Singer, T. P. In Chemistry and Biochemistry of Flavoenzymes; Muller, F., Ed.; CRC Press: Boca Raton, FL, 1991; Vol. 2, p 437.
3. Zeller, E. Classification and Nomenclature of Monoamine Oxidase and Other Amine Oxidases: Structure, Function and Altered Functions; Academic Press: New York. 1979.
4. Wouters, J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem. 1998, 5, 137-162.
5. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: Safety and future. Neurotoxicology 2004, 25, 11-20.
6. Rudorfer, M. V.; Potter, V. Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 1989, 37, 713-738.
7. Gerlach, M.; Double, K.; Reichmann, H.; Riederer, P. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's diseases. J. Neural Transm. Suppl. 2003, 167-193.
8. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's desease. Neurotoxicology 2004, 25, 271-277.
9. Cesura, A. M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 1992, 38, 171-297.
10. Youdim, M. B. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr. Scand. Suppl. 1995, 386, 5-7.
11. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11, 1983-1993.
12. Carrieri, A.; Carotti, A.; Barreca, M. L.; Altomare, C. Binding models of reversible inhibitors to type-B monoamine oxidase. J. Comput. Aid.- Mol. Des. 2002, 16, 769-778.
13. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO-A): Relation to the structures of rat MAO-A and human MAO B. Proc. Natl. Acad. Sci. 2005, 102, 12684-12689.
14. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi, A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindane class. J. Med. Chem. 2004, 47, 1767-1774.
15. Mevedev, A. E.; Veselovsky, A. V.; Shvedov, V. I.; Tikhonova, T. A.; Moskvitinia, T. A.; Fedotova, O. A.; Axenova, L. N.; Kamyshanskaya, A. Z.; Kirkel, A. Z. and Ivanov, A. Inhibition of monoamino oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J. Chem. Inf. Comput. Sci. 1998, 38, 1137-1144.
16. Nunez, M. B.; Maguna, F. P.; Okulik, N. B.; Castro, E. A. QSAR modeling of the MAO inhibitory activity of xanthone derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 5611-5617.
17. Todeschini, R and Consonni, V. Handbook of Molecular Descriptors; Wiley VCH: Weinheim, Germany, 2000.
18. Kier, L. B.; Hall, L. H. Topological Indices and Related Descriptors in QSAR and QSPR; Gordon and Breach Science Publishers: Amsterdam, 1999; pp 445-489.
19. Estrada E.; Uriarte, E. Recent advances on the role of topological indices in drug design discovery research. Curr. Med. Chem. 2001, 8, 1573-1588.
20. Estrada, E.; Uriarte, E.; Montera, A.; Teijeira, M.; Santana, L.; De Clercq, E. A novel approach for the virtual screening and rational design of anticancer compounds. J. Med. Chem. 2000, 43, 1975-85.
21. Karelson, M.; Lobanov, V. S.; Katritzky, A. R. Quantum-chemical descriptors in QSAR/QSPR studies. Chem. Rev. 1996, 96, 1027-1043.
22. Bultinck, P.; Langenaeker, W.; Carbo-Dorca, R.; Tollenaere, J. P. Fast calculation of quantum chemical molecular descriptors from the electronegativity equalization methodology. J. Chem. Inf. Comput. Sci. 2003, 43, 422-428.
23. Sanderson, R. T. Electronegativity and bond energy. J. Am. Chem. Soc. 1983, 105, 2259-2261.
24. Mortier, W. J.; Ghosh, S. K.; Shankar, S. Electronegativity-equalization method for the calculation of atomic charges in molecules. J. Am. Chem. Soc. 1986, 108, 4315-4320.
25. Freund, J. A.; Poschel, T., Eds. Stochastic processes in physics, chemistry, and biology. In Lecture Notes in Physics; Springer-Verlag: Berlin, Germany. 2000.
26. González-Díaz, H.; Agüero, G.; Cabrera, M. A.; Molina, R.; Santana, L.; Uriarte, E.; Delogu, G.; Castanedo, N. Unified Markov thermodynamics based on stochastic forms to classify drugs considering molecular structure, partition system, and biologic species. Distribution of the antimicrobial G1 on rat tissues. Bioorg. Med. Chem. Lett. 2005, 15, 551-557.
27. González-Díaz, H.; Cruz-Monteagudo, M.; Molina, R.; Tenorio, E.; Uriarte, E. Predicting multiple drugs side effects with a general drug-target interaction thermodynamic Markov model. Bioorg. Med. Chem. 2005, 13, 1119-1129.
28. González-Díaz, H.; Torres-Gómez, L. A.; Guevara, Y.; Almeida, M. S.; Molina, R.; Castanedo, N.; Santana, L.; Uriarte, E. Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5D indices for the discovery of antibacterials. J. Mol. Mod. 2005, 11, 116-123.
29. Van Waterbeemd, H. Discriminant analysis for activity prediction. In Chemometric Methods in Molecular Design. Method and Principles in Medicinal Chemistry; Manhnhold, R., Krogsgaard-Larsen, P., Timmerman, H., Eds.; VCH: Weinhiem, 1995; Vol. 2, pp 265-282.
30. Kleeman, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances, 4th ed.; George Thieme Verlag: Stuttgart, 2001.
31. Negwer, M. Organic Chemical Drugs and Their Synonyms; Akademie-Verlag: Berlin, 1987.
32. Santana, L.; Uriarte, E.; Roleira, F.; Mihazes, N.; Borges, F. Furocoumarins in medicinal chemistry. Synthesis, natural occurrence and biological activity. Curr. Med. Chem. 2004, 11, 3239-3261.
33. Gnerre, C.; Catto, M.; Francesco, L.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase by functionalized coumarin derivatives: Biological activities, QSAR, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
34. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: Biological activity and computational study. Bioorg. Med. Chem. Lett. 2004, 14, 3697-3703.
35. Antonello, C.; Marciani-Magno, S.; Gia, O.; Carlassare, F.; Baccichetti, F.; Bordin, F. Diethylaminoalkyloxycoumarin and -furocoumarin derivatives. Il Farmaco, Ed. Sci. 1979, 34, 139-156.
36. Hansen, J. B.; Bjerring, P.; Buchardt, O.; Ebbesen, P.; Kanstrup, A.; Karup, G.; Knudsen, P. H.; Nielsen, P. E.; Norden, B.; Ygge, B. Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8- methoxy-, 5-[[(3-aminopropyl)oxy] methyl]- and 8-[(3-aminopropyl)oxy]psoralen derivatives. J. Med. Chem. 1985, 28, 1001-1010.
37. Nakamura, Y. Photocrosslinking and the cleavage of DNA by iron complex-substituted psoralen. Chem. Lett. 1989, 1, 51-54.
38. Gia, O.; Tonconi, M. T.; Uriarte, E. Benzo and tetrahydrobenzofurocoumarins: New potential photochemotherapeutic drugs. Il Farmaco 1997, 52, 289-294.
39. Corda, L. Delogu, G.; Favretto, D.; Maccioni, E. Podda, G.; Santana, L.; Tomaselli, P.; Traldi, P.; Uriarte, E. Synthesis and mass spectrometric investigation of some new coumarin derivatives. Rapid. Comm. Mass Spectrom. 1998, 12, 2041-2046.
40. Dalla Via, L.; Gia, O.; Viola, G.; Bertoloni, G.; Santana, L.; Uriarte, E. Photobiological studies of new cyclopentenepsoralens. Il Farmaco 1998, 12, 638-644.
41. Terán, C.; Miranda, R.; Santana, L.; Teijeira, M.; Uriarte, E. Synthesis of angular and linear benzofurocoumarins. Synthesis 1997, 12, 1384-1386.
42. Dalla Via, L.; Gia, O.; Marciani-Magno, S.; Teijeira, M.; Santana, L.; Uriarte, E. New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: Synthesis, DNA interacction and antiproliferative activity. J. Med. Chem. 1999, 42, 4405-4413.
43. Rodighiero, G.; Antonello, C. Sintesi di alcuni derivati 3-ammino-cumarinici e prime notizie sulle loro propietà antibatteriche. Bolletino Chim. Farm. 1958, 97, 592-601.
44. Antonello, C.; Marciani-Magno, S.; Baessato, O.; Palumbo, M. 3-Amino- and 3-oxy-derivatives of psoralen: Preparation and interactions with DNA. Il Farmaco, Ed. Sci. 1981, 36, 565-584.
45. Méndez-Álvarez, E.; Soto-Otero, R.; Sánchez-Sellero, I.; López-Rivadulla, L. M. Inhibiton of brain monoamine oxidase by adducts of 1,2,3,4-tetrahiisoquinoline with components of cigarette smoke. Life Sci. 1997, 60, 1719-1727.
46. Méndez-Álvarez, E.; Soto-Otero, R.; Sánchez-Sellero, I.; López-Rivadulla, L. M. In vitro inhibition of catalase activity by cigarette smoke: Relevance for oxidative stress. J. Appl. Toxicol. 1998, 18, 443-448.